Cristal Therapeutics progresses nanomedicine CriPec-docetaxel to Phase Ib development
This nanomedicine candidate is specifically designed to enable enhanced tumour accumulation and local drug release at the target site, to boost the therapeutic efficacy and to overcome the shortfalls associated with current docetaxel products.
Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has begun a Phase Ib clinical program of its lead nanomedicine candidate CriPec-docetaxel in patients with solid tumours. This CriPec-docetaxel program will evaluate the optimal frequency and dosing schedule for Phase II clinical efficacy trials, as well as examining the distribution and uptake of this nanomedicine.
CriPec-docetaxel is a new drug modality that entraps docetaxel (Taxotere), a clinically validated chemotherapy, as its therapeutic payload into nanoparticles. This nanomedicine candidate is specifically designed to enable enhanced tumour accumulation and local drug release at the target site, to boost the therapeutic efficacy and to overcome the shortfalls associated with current docetaxel products, such as the toxic systemic side effects.
The Phase Ib program is being initiated based on preliminary positive Phase Ia results from the open-label, safety and pharmacokinetic study, which suggest that CriPec-docetaxel can be administered at therapeutic dose levels that are safe and well tolerated. CriPec-docetaxel also demonstrated a unique and improved pharmacokinetic profile over Taxotere and other docetaxel-based drug candidates.
Dr Joost Holthuis, Cristal Therapeutics’ CEO and co-founder said: “Progressing CriPec-docetaxel to a Phase Ib program is an important milestone, and highlights the unique preliminary safety and pharmacokinetic data produced from the Phase Ia study. We look forward to the results of the consolidated Phase I program.”
The Phase Ib study is being conducted at the Department of General Medical Oncology, University Hospitals Leuven, Belgium and at the following three clinical centres across the Netherlands: Erasmus M.C. Cancer Institute, Rotterdam, the Vrije Universiteit Medical Centre, Amsterdam and the University Medical Centre Groningen.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.